{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-359418","form_type":"8-K","ticker":"AMLX","cik":"0001658551","company_name":"Amylyx Pharmaceuticals, Inc.","filed_at":"2026-08-20T21:28:20+00:00","discovered_at":"2026-08-20T21:30:14.034230+00:00","generated_at":"2026-08-20T21:30:32.202553+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Amylyx prices $471.7M equity offering to fund avexitide launch","bullets":["14,090,000 shares at $35.50/share; 30-day option for 2,113,500 more.","Net proceeds ~$471.7M (~$542.5M if option fully exercised).","Proceeds to fund potential U.S. launch of avexitide, R&D, working capital.","Offering expected to close Aug 21, 2026; underwriters: Leerink, Morgan Stanley, Guggenheim, LifeSci."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-359418","json":"https://secwatch.observer/filing/0001193125-26-359418.json","markdown":"https://secwatch.observer/filing/0001193125-26-359418.md","text":"https://secwatch.observer/filing/0001193125-26-359418.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1658551/000119312526359418/0001193125-26-359418-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1658551/000119312526359418/d179247d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-20T21:30:32.202553+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}